Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOTOR Study: Neuromuscular Monitoring in Pediatric Anesthesia
2024-517057-27-00Phase 3Authorised
- Sponsor
- Istituto Giannina Gaslini
- Start
- Jun 2025
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised trial of Sugammadex in None (2 arms), sponsored by Istituto Giannina Gaslini. Primary endpoint: Percentage of sugammadex use in each arm at the end of anesthesia. Planned start Jun 2025; status: authorised.
02
Drugs
Sugammadex
Beyond the preview
Go deeper on 2024-517057-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517057-27-00.